A Randomized, Open-label Study of the Safety and Efficacy of Multi- Vessel Intracoronary Delivery of Allogeneic Cardiosphere-Derived Cells in Patients With Cardiomyopathy Secondary to Duchenne Muscular Dystrophy

Trial Profile

A Randomized, Open-label Study of the Safety and Efficacy of Multi- Vessel Intracoronary Delivery of Allogeneic Cardiosphere-Derived Cells in Patients With Cardiomyopathy Secondary to Duchenne Muscular Dystrophy

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs CAP-1002 (Primary)
  • Indications Cardiomyopathies; Duchenne muscular dystrophy
  • Focus Adverse reactions
  • Acronyms HOPE-DUCHENNE
  • Sponsors Capricor
  • Most Recent Events

    • 29 Jun 2017 According to a Capricor Therapeutics media release, interim six-month safety and efficacy results from the study will be presented at the 2017 Parent Project Muscular Dystrophy (PPMD) Annual Connect Conference.
    • 10 Jun 2017 Biomarkers information updated
    • 25 Apr 2017 According to a Capricor Therapeutics media release, the company expects to report top-line 12-month results from this trial in the fourth quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top